Determination of reference values of acetyl and butyryl cholinesterase activities in Serbian healthy population
Abstract
Background/Aim. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) are important biomarkers of exposure to organophosphorus and carbamate insecticides. Since the estimation of the level of cholinesterase inhibition depends on the normal values which may vary in different populations, it is important to determine them in our population, which so far has not been done. Therefore, the aim of this study was to determine the reference values for AChE and BuChE in a healthy population of adults in the Republic of Serbia. Methods. The AChE activity was measured by spectrophotometry (λ = 412 nm), using a modified Ellman’s method. BuChE activity was determined by the integrated chemical system (Dimension RxLMax) with ready-made reagent cartridge for analysis. The examinees were healthy voluntary blood donors from the Institute of Transfusiology and Hemobiology, Military Medical Academy in Belgrade, Serbia. Statistical Package for Social Sciences (SPSS) software program was used for data processing. Results. In the group of 851 persons, there were 728 males and 123 females. The mean age was 39.1 ± 11.6 years. For all of them, erythrocyte AChE activity was done while BuChE was determined in 205 persons (169 males and 36 females). Their mean value of acetylcholinesterase activity was 8,090.6 ± 1,976.7 IU/L, and of butyrylcholinesterase activity was 14,556.6 ± 4,078.1 U/L. Due to lack of normal data distribution in male group (both enzymes), reference ranges were estimated as 2.5 and 97.5 percentiles. Conclusion. The results of this pilot study on cholinesterase in healthy population in the Republic of Serbia which has now been done for the first time, indicate the need for considering their wider ranges of when estimating the severity of poisoning. However, further study for BuChE with the inclusion of a larger number of females and data for body weight of the examinees, in order to get more precise reference limits, is suggested.
References
Bosak A, Katalinić M, Kovarik Z. Cholinesterases: structure, role, and inhibition. Arh Hig Rada Toksikol 2011; 62(2): 175−90. (Serbian)
Whittaker VP. How the cholinesterases got their modern names. Chem Biol Interact 2010; 187(1−3): 23−6.
Holmstedt B. Cholinesterase inhibitors: An introduction. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibi-tors. London: Martin Dunitz Ltd; 2000. p. 1−8.
Čolović M, Krstić D, Lazarević-Pašti T, Bondžić A, Vasić V. Ace-tylcholinesterase inhibitors. Pharmacology and Toxicology. Curr Neuropharmacol 2013; 11(3): 315−35.
Pohanka M. Cholinesterases, a Target of pharmacology and toxicology. Biomed Pap 2011; 155(3): 219−30.
Chen X, Fang L, Liu J, Zhan C. Reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of acetylcholine. J Phys Chem B 2011; 115(5): 1315−22.
Davis L, Britten JJ, Morgan M. Cholinesterase Its significance in anaesthetic practice. Anaesthesia 1997; 52(3): 244−60.
Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholines-terase as a prognostic marker: A review of the literature. J Ca-chexia Sarcopenia Muscle 2013; 4(1): 31−9.
Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficien-cy: a comprehensive review of genetic, acquired, and drug in-fluences. AANA J 2010; 78(4): 313−20.
Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: Register-based study of over 700, 000 elderly patients. Drugs Aging 2008; 25(10): 871−7.
Karalliedde L, Henry J. The acute cholinergic syndrome. In: Karraliedde L, Feldman S, Henry J, Marrs T, editors. Organophosphates and health. London: Imperial College Press; 2001. p. 109−40.
Brock A, Brock V. Factors affecting inter-individual variation in human plasma cholinesterase activity: body weight, height, sex, genetic polymorphism and age. Arch Environ Contam Toxicol 1993; 24(1): 93−9.
Christenson WR, van Goethem DL, Schroeder RS, Wahle RS, Dass PD, Sangha GK, et al. Interlaboratory cholinesterase determina-tions and the effect on the results of statistical evaluation of cholinesterase inhibition. Toxicol Lett 1994; 71(2): 139−50.
Trundle D, Marcial G. Detection of Cholinesterase Inhibition. The significance of Cholinesterase Measurements. Ann Clin Lab Sci 1988; 18(5): 345−52.
Elman G, Courtney D, Andres V, Featherstone R. A new and rapid colorimetric determination of acetylcholinesterase activity. Bi-ochem Pharmacol 1961; 7: 88−9.
Reiner E, Šinko G, Škrinjarić-Špoljar M, Simeon-Rudolf V. Com-parison of protocols for measuring activities of human blood cholinesterases by the Ellman method. Arch Hig Rada Toksi-kol 2000; 51: 13−8.
Aldridge WN, Davies DR. Determination of cholinesterase ac-tivity in human blood. BMJ 1952; 1(4765): 945–7.
Worek F, Mast U, Kiderlen D, Diepold C, Eyer P. Improved de-termination of acetylcholinesterase activity in human whole blood". Clin Chim Acta 1999; 288(1-2): 73−90.
Gal EM, Roth E. Spectrophotometric methods for determina-tion of cholinesterase activity. Clin Chim Acta 1957; 2(4): 316–26.
Sánchez LH, Medina OM, Gómez G, González CI, Flórez-Vargas Ó. Laboratory genetic-based reference values for cholinesterase activity in a Colombian population: A step forward in per-sonalized diagnostics. Biomedica 2015; 35 Spec: 20−9.
Lepage L, Schiele F, Gueguen R, Slest G. Total Cholinesterase in Plasma: Biological Variations and Reference Limits. Clin Chem 1985;31(4): 546-550.
Chan L, Balabaskaran S, Delilkan AE, Ong LH. Blood cholines-terase levels in a group of Malaysian blood donors. Malays J Pathol 1994; 16(2): 161−4.
Abdullat EM, Obeidat NM, Al-Jaghbir MT, Al-Hiari YM, Al-Hadidi K. Establishing the Cholinesterase Levels in Jordan: An Investigation and Monitoring Model for Pesticide Outbreak. Med J 2015; 49(3): 129−38.
Westgard JO, Hund MR, Lahmeyer BL. Estimates of Normal Ranges for 15 Determinations on the Du Pont Pont Automat-ic Clinical Analyzer. Madison, WI: Dept. of Medicine and Clin-ical Laboratories, University of Wisconsin Center for Health Science; 2003.
Sunderman FW Jr. Current concepts of "normal values," "refer-ence values," and "discrimination values," in clinical chemistry. Clin Chem 1975; 21(13): 1873−7.
Solberg HE. The IFCC recommendation on estimation of ref-erence intervals. The Ref Val Program. Clin Chem Lab Med 2004; 42(7): 710–714.
Harris EK, Boyd JC. On dividing reference data in to subgroups to produce separate reference ranges. Clin Chem 1990; 36(2): 265−70.
Horowitz GL, Altaie CS, Boyd JC, Ceriotti F, Garg U, Horn P. Defining, Establishing, and Ver ifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd ed. Wayne, PA: CLSI; 2008.
Guidi GC, Salvagno GL. Reference intervals as a tool for total quality management. Biochem Med 2010; 20(2): 165−72.
Brock A, Brock V. Plasma cholinesterase activity in a healthy population group with no occupational exposure to known cholinesterase inhibitors: Rrelative influence of some factors related to normal inter- and intra-individual variations. Scand J Clin Lab Invest 1990; 50(4): 401−8.
Mayo Medical Laboratories. Pseudocholinesterase, Total, Se-rum. U.S.: Mayo Clinic. Available from: http://www.mayomedicallaboratories.com/testcatalog/Clinical+and+Interpretive/8
Test name (Cholinesterase, Serum, Plasma, RBC). U.S.: Quest Diagnostics clinical laboratory. Available from: http://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=39481
Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnosis.St. Louis: W. B. Saunders Company; 2012.